🇺🇸 FDA
Patent

US 11426409

Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers

granted A61KA61K31/519A61K45/06

Quick answer

US patent 11426409 (Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers) held by The Regents of the University of Colorado expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/519, A61K45/06, A61P, A61P35/00